in other forms of vasculitis Recommendation: For patients with active, severe EGPA, we conditionally recommend treatment with cyclo phosphamide or rituximab over mepolizumab for remission induction. The efficacy of mepolizumab in severe EGPA has not been established, as patients with active, severe disease were excluded from the randomized trial Remission induction for active, nonsevere disease Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating